Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia - Wikidata - awgldk - TriplyDB

Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia

Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia

http://www.wikidata.org/entity/Q35383040

about

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.The neuropsychiatric translational revolution: still very early and still very challenging.Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis.Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia.Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity.Homocysteine levels in schizophrenia and affective disorders-focus on cognition.Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis.Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11.Realising stratified psychiatry using multidimensional signatures and trajectories.The epigenome and postnatal environmental influences in psychotic disorders.Vitamin supplementation in the treatment of schizophrenia.Drug repurposing and emerging adjunctive treatments for schizophrenia.Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence.Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial.Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits.Neuregulin 1 Promotes Glutathione-Dependent Neuronal Cobalamin Metabolism by Stimulating Cysteine Uptake.Improving Current Treatments for Schizophrenia.Epigenetic mechanisms in the pathophysiology of psychotic disorders Conceptualization and treatment of negative symptoms in schizophrenia.Enhancement of recovery from mental illness with l-methylfolate supplementation.Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.A Cross-Sectional Study of Dietary and Genetic Predictors of Blood Folate Levels in Healthy Young Adults.Nutritional Deficiencies and Clinical Correlates in First-Episode Psychosis: A Systematic Review and Meta-analysis.Negative symptoms of psychosis: A life course approach and implications for prevention and treatment.Natural Medicines for Psychotic Disorders: A Systematic Review.S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life.Understanding the schizophrenia prodrome.

P2860

Q22241447-24B2E0C7-5974-4A92-8A92-0C2441A67917 Q28066603-D5D6D8FE-1BC9-4E92-BCBB-0725C608C6ED Q28248117-1C461604-5B4A-44F8-9508-FDA3A5F5BA6D Q30382281-EFA171AC-9D10-48BA-BF5A-36DE0759581D Q33599127-20FDAF93-8798-4923-A268-6A51D680451E Q34018212-CBC534AB-89EB-46C6-80AE-5478F8DDE73E Q34047983-AB990A3B-8636-4C89-9C04-3DB82EFEACB3 Q34048609-EC14C48D-2383-4633-AB52-E28B54A04B63 Q34228522-EE41E337-89F2-4BAC-8363-17E4C1F0B8DC Q34292122-F697B92D-FDEA-40E9-9409-5244D6438DA3 Q34484974-E3D9BAF5-A4DF-46E9-8E7D-21F0127874A2 Q35712593-FE6E6503-62D3-4A1A-AEFB-6C87346E7E59 Q36063627-6F2C4839-6DD1-4343-A12A-FAA0E70CCA26 Q36930839-ECF9CF1A-368E-4D05-BAEA-7DAE404C8E4E Q36940052-AD3A081D-305C-4722-AA3A-FB8721CBCDCC Q37591548-AC6A2EAD-4FBE-49A5-B469-CC4E6D3B13CC Q38189293-F88C0A45-E7A0-4F52-BDF1-1127F636CD0E Q38213305-8343E8F5-0C41-438D-BAB1-3FD3C752FC6E Q38417631-F7F5969E-18F9-4858-A3B5-2A866E28BA60 Q38583706-C7B5C615-5957-4C86-9CBF-FC86FB1C37AB Q38611829-2D5F141A-2B22-49A3-A2BC-C340ED301906 Q38624047-98FEA4EA-1CAF-40ED-8078-3503DCDBBF92 Q38779897-A7F57E8F-578D-476B-9B9F-04E62FE78490 Q38955513-78751898-3665-429C-A331-5F6BFFB8F316 Q39010677-900E7F1E-18DD-43DC-A2E3-386073FC655F Q39178474-8686CFEA-09F0-4058-834C-CFEAEE55B3D2 Q39361549-69F74264-993E-45E9-A78F-D43E61CD6FD4 Q41059882-C9DCBE7F-ECD1-4215-90B0-55D4FF0D4EF4 Q42368242-FFF62B6F-043D-47DA-BB7A-3B2620CE894B Q47567371-6F98426D-A23C-46A6-9341-AF91831F643F Q47587674-7CEC893A-643B-47F3-B974-E3F2219C5D2B Q49363880-D08C56CB-5283-48C7-9595-A2AE79F660BB Q50013273-660643B7-8283-4EBD-8BFC-61D1EF1DA6D4 Q55030256-ADF15AF9-4189-4408-864E-72473592C844

P2860

Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia

http://www.wikidata.org/entity/Q35383040

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Randomized multicenter investi ...... pplementation in schizophrenia

@ast

Randomized multicenter investi ...... pplementation in schizophrenia

@en

type

label

Randomized multicenter investi ...... pplementation in schizophrenia

@ast

Randomized multicenter investi ...... pplementation in schizophrenia

@en

prefLabel

Randomized multicenter investi ...... pplementation in schizophrenia

@ast

Randomized multicenter investi ...... pplementation in schizophrenia

@en

P1433

Q35383040-F597D8C4-6711-4090-BACF-1B72C505D045

P1476

Q35383040-936206B7-B2E0-43D4-8CD2-883301A809D6

P2093

Q35383040-8C4C7198-C1EA-43F4-BA00-219177132327

Q35383040-A998A50E-8413-45C3-8CC6-1338E32B49C5

Q35383040-D00F8F6A-3480-4C8A-8106-E310D73BC8E5

Q35383040-FA8D9100-7AD3-476C-B332-9F50E36B87B1

Q35383040-FB9D7476-226D-412D-B54E-45BAA5051CFF

P2860

Q35383040-08C9AC0E-6573-4892-9393-2BDAD919DCD4

Q35383040-128D701E-2FE9-4B14-A4BC-AD93C59646F3

Q35383040-14BB1C2B-4831-419B-91CF-A73A6E686096

Q35383040-160FC999-381B-4A60-B0D9-36901879ABA1

Q35383040-1E941FCD-F091-4AF8-8B9A-AEB72792D33D

Q35383040-20C126AE-AEB1-44E6-81C6-AA50F2A17E8A

Q35383040-2CA735B9-09ED-42D8-AFD8-AF0CF88431D2

Q35383040-2F9DEC7A-9E9C-4756-8F60-FB71C2BFFDE1

Q35383040-34966B8E-A1B2-4C56-A1FB-7720F1EF2026

Q35383040-3B6D5BE5-A62D-4E8D-A46F-EE28EC5B8D63

P304

Q35383040-5BE75EF4-1DE1-46FF-9259-9B3178BF372A

P31

Q35383040-319DD4F6-EC58-4F45-A3CD-E1296C6A4D8E

P356

Q35383040-E16B288B-5CC2-4A68-A8DA-04AD207D9AD6

P407

Q35383040-65A945F8-F4EE-444E-829D-C147711B1CA1

P433

Q35383040-6DDD43B3-E103-483C-8459-B03BD1C7E7CB

P478

Q35383040-5C3A74B1-97C2-4A07-83A7-8E1827354929

P50

Q35383040-3C10B0D6-9973-4CAA-A00D-12B404155C23

Q35383040-76B2DA25-6124-44B5-8117-741024B2B4FC

Q35383040-89488731-0D20-4219-8B77-505CD85912F9

Q35383040-89499CC5-2F90-4BF0-95AB-5C0FA41952B7

Q35383040-B97E3BE0-8A15-4573-86E4-F9CDBEC8E86F

P577

Q35383040-E129DFAA-EEFD-4BFA-A985-14117284F02B

P698

Q35383040-2EE92F4C-7680-46CD-83B7-0E5A03E21D95

P921

Q35383040-04467731-4D4E-47FB-8051-A1D5F5801839

Q35383040-3B2DB608-13AC-4AAB-A0D0-F20B3355E817

Q35383040-453F9F37-F212-4A16-AB60-CE52D4CB831A

Q35383040-94f4d5aa-dfd4-4a5e-9608-7145469a96c4

P932

Q35383040-299D4992-66D0-4460-872E-9C18B7261188

P356

JAMAPSYCHIATRY.2013.900

P1433

JAMA Psychiatry

P1476

Randomized multicenter investi ...... pplementation in schizophrenia

@en

P2093

Gail C Galendez

http://www.w3.org/2001/XMLSchema#string

J Steven Lamberti

http://www.w3.org/2001/XMLSchema#string

Jordan W Smoller

http://www.w3.org/2001/XMLSchema#string

Lisa H Raeke

http://www.w3.org/2001/XMLSchema#string

Michele Hill

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

Schizophrenia after prenatal famine. Further evidence

Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

Homocysteine lowering with folic acid and B vitamins in vascular disease

Homocysteine lowering and cardiovascular events after acute myocardial infarction

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.

Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia.

A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status.

Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

P304

481-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAPSYCHIATRY.2013.900

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Joshua L Roffman

Noah J Silverstein

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23467813

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4394629

http://www.w3.org/2001/XMLSchema#string